Nang Kuang and biosyn Enter into an Exclusive Agreement to Commercialize Selenase ® in Chinese Mainland
In January 2023, Nang Kuang has entered into a long-term exclusive licensing partnership with biosyn Arzneimittel GmbH（biosyn）for the commercialization of Selenase ® (generic name: sodium Selenite Injection) for the treatment of selenium deficiency.
biosyn Arzneimittel GmbH is a pharmaceutical and biotech company headquartered in Fellbach. biosyn specializes in trace elements, is a global market leader for high-dose selenium injections.
For more information, visit www.nangkuang-med.com